Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>The company attributed the strong topline to investments in technology and personnel made in recent quarters to support expected growth.</li><li>The Caduceus sub-contract is not included in guidance and so therefore could provide upside, depending on when it comes on stream.</li><li>Moreover, SYRA is optimistic about potential new federal business.</li></ul>

The company attributed the strong topline to investments in technology and personnel made in recent quarters to support expected growth.The Caduceus sub-contract is not included in guidance and so therefore could provide upside, depending on when it comes on stream.Moreover, SYRA is optimistic about potential new federal business.

SYRA: Reiterates Revenue Guidance Up 64%-100% Y/Y, Diversifying, Growing Pipeline

<ul><li>Lantern Pharma uses AI & data to identify drug responders, uncover mechanism of action & rescue failed drugs.</li><li>It is developing LP-300 for non- & never smoker NSCLC in the Harmonic trial.</li><li>Secondary candidates include LP-100 for mCRPC and LP-184 and LP-284 which are in clinical development for multiple biomarker-defined tumors and hematological cancers, respectively.</li></ul>

Lantern Pharma uses AI & data to identify drug responders, uncover mechanism of action & rescue failed drugs.It is developing LP-300 for non- & never smoker NSCLC in the Harmonic trial.Secondary candidates include LP-100 for mCRPC and LP-184 and LP-284 which are in clinical development for multiple biomarker-defined tumors and hematological cancers, respectively.

Equity Research Focusing on the Consumer Sector, Small Cap Consumer Research

Small Cap Consumer Research

Equity Research Focusing on the Consumer Sector

Small Cap Consumer Research, LLC is a leading company-sponsored equity research provider focusing on the consumer sector (apparel, brand licensing and specialty retailing segments).

<ul><li>We are reiterating our Buy rating, $14 price target, and projections for Lands' End after reviewing the May catalogs for 2023 and 2024.</li><li>The overwhelming focus for this month is swim, one of the core categories for the company.</li><li>Lands' End continues to drive deeper levels of newness to capture higher pricing and create a sense of urgency for purchases.</li></ul>

We are reiterating our Buy rating, $14 price target, and projections for Lands' End after reviewing the May catalogs for 2023 and 2024.The overwhelming focus for this month is swim, one of the core categories for the company.Lands' End continues to drive deeper levels of newness to capture higher pricing and create a sense of urgency for purchases.

LE: Snapping the Catalog: The "New" Lands' End Swim; Reiterate Buy & $14 PT

External broker reports(aggregated public sources), Nordea

Nordea

External broker reports(aggregated public sources)

Nordea is the bank in the Nordics dedicated to serving corporations and institutional customers. Our offering includes a diverse range of financing, cash management and payment services, investment banking, capital markets products, securities services and more. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Macroeconomics

<ul><li>wedish housing prices have been close to unchanged ever since the end of the downturn 15 months ago.</li><li>Prices rose slightly in the first quarter of this year and increased by almost 1 percent over the month in April, which strengthens our view that the housing market has turned a corner.</li><li>As we argued in January, there was a chance that falling interest rate expectations could lift prices before the first rate cut from the Riksbank, which also happened.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

wedish housing prices have been close to unchanged ever since the end of the downturn 15 months ago.Prices rose slightly in the first quarter of this year and increased by almost 1 percent over the month in April, which strengthens our view that the housing market has turned a corner.As we argued in January, there was a chance that falling interest rate expectations could lift prices before the first rate cut from the Riksbank, which also happened.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

External broker reports(aggregated public sources), International Securities

International Securities

International Securities’ equity research analysis and advisory have been a vital source of market intelligence for our distinguished clients over the years. The equity research team’s main objective is to cover listed equities and to provide thoughtful, insightful, differentiated and timely research that can help clients make informed decisions. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>ADNOC Drilling posted 1Q24 core profit after tax of USD275mn, up 26% YoY (-4% QoQ), in line with our estimates</li><li>The company also revised its dividend policy, enhancing the annual increase to 10% for 2024-2028 from 5%, previously</li><li>The YoY jump in profits was led by rampant rig addition which reached 137 rigs in 1Q24 versus 115 rigs in 1Q23</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

ADNOC Drilling posted 1Q24 core profit after tax of USD275mn, up 26% YoY (-4% QoQ), in line with our estimatesThe company also revised its dividend policy, enhancing the annual increase to 10% for 2024-2028 from 5%, previouslyThe YoY jump in profits was led by rampant rig addition which reached 137 rigs in 1Q24 versus 115 rigs in 1Q23Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

ADNOC Drilling: 1Q24 Core Profit up 26% YoY (-4% QoQ) To USD275mn, in Line with Estimates

SYRA: Reiterates Revenue Guidance Up 64%-100% Y/Y, Diversifying, Growing Pipeline

The company attributed the strong topline to investments in technology and personnel made in recent quarters to support expected growth. The...

Zacks Small Cap Research

LTRN: Expanding Horizons into Asia

Lantern Pharma uses AI & data to identify drug responders, uncover mechanism of action & rescue failed drugs. It is developing LP-300 for...

Zacks Small Cap Research

LE: Snapping the Catalog: The "New" Lands' End Swim; Reiterate Buy & $14 PT

We are reiterating our Buy rating, $14 price target, and projections for Lands' End after reviewing the May catalogs for 2023 and 2024. The...

Small Cap Consumer Research

Swedish housing market: Waking up

As we argued in January, there was a chance that falling interest rate expectations could lift prices before the first rate cut from the Riksbank,...

Nordea

ADNOC Drilling: 1Q24 Core Profit up 26% YoY (-4% QoQ) To USD275mn, in Line with Estimates

We expect 4-year (2023-2027) EBITDA CAGR of 10% while the stock offers FY24 revised dividend yield of 4.6%. We maintain Buy with Fair Value of...

International Securities